EMPAGLIFLOZIN

Brand name:

• Jardiance®

Pharmaceutical company:

Boehringer Ingelheim Pty Ltd

Condition/indication:
(therapeutic use)

• Chronic heart failure

PBAC Submission type:

Change to existing listing (Category 4)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2024

Related medicines:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

23/04/2024

Lodgement of required documentation:

02/05/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 16/05/2024

Status:

Finalised

Government processes:

Commenced on 16/05/2024

Medicine listed on the PBS:

01/08/2024 (see PBS schedule)

---